EP. 1: FDA Grants Fast Track Designation to R289 for LR-MDS Treatment
R289, a dual IRAK1/4 inhibitor, has received fast track status from the FDA for treating transfusion-dependent lower-risk MDS in patients with inadequate responses to prior therapies.
